Improving patient access to life-enhancing medications
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercializing branded and generic pharmaceuticals.
We have a 40-year track record of innovation and success developing new oral drug delivery systems and these technologies have been successfully commercialized in numerous products that continue to be marketed around the world.

We offer patients better, safer & more accessible medicines.
For investors
More for investorsNews & Events


Mayne Pharma announces sale of Metrics Contract Services
10 Aug 2022
Mayne Pharma today announced that it has entered into an agreement with Catalent to sell Metrics Contract Services for a total cash consideration of US$475 million (~A$679 million)
Learn more


Mayne Pharma and Mithra announce FDA approval of Haloette, a generic version of Nuvaring
8 Aug 2022
Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA are pleased to announce that the US Food and Drug Administration (FDA) has granted approval of the Abbreviated New Drug Application (ANDA) for HALOETTE® (etonogestrel and ethinyl estradiol) vaginal hormonal contraceptive ring
Learn more


NEXTSTELLIS® oral contraceptive nominated for the 2022 Prix Galien USA Award for Best Pharmaceutical Agent
2 Aug 2022
Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA are pleased to announce NEXTSTELLIS® (drospirenone and estetrol tablets) has been nominated for the 2022 Prix Galien USA Award for Best Pharmaceutical Agent.
Learn more


Mayne Pharma and GoodRx announce new initiative to increase awareness of NEXTSTELLIS®
29 Jul 2022
Mayne Pharma Group Limited is pleased to announce a new strategic collaboration with GoodRx, a leading consumer-focused digital healthcare platform in the U.S. The collaborative initiative will deliver an enhanced direct-to-consumer program aimed at building awareness of NEXTSTELLIS® (E4/DRSP) oral contraceptive availability in the United States.
Learn more


NEXTSTELLIS® oral contraceptive now available in Australia
26 Jul 2022
Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA are pleased to announce NEXTSTELLIS® (14.2 mg of estetrol and 3 mg drospirenone tablets), a first-of-its kind oral contraceptive with a novel estrogen is now available in Australia.
Learn more


New Chief Financial Officer appointment
22 Jul 2022
Mayne Pharma Group Limited is pleased to announce that Mr Aaron Gray has been appointed as Chief Financial Officer (CFO), effective 29 August 2022.
Learn more